Fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3, and FGFR4) are receptor tyrosine kinases involved in cell proliferation, cell differentiation, cell migration, and cell survival¹
FGFR genetic alterations have been implicated as oncogenic drivers in a variety of tumor types. Some examples of these genetic alterations are FGFR gene amplifications, activating mutations, and chromosomal translocations^2,3
Therapeutic targeting of FGFRs implicated in oncogenesis is a major area of drug development research⁴

Learn about FGFRs

TRUSELTIQ is approved in the U.S. and limited other markets. In the U.S., visit TRUSELTIQ.com for more information. Click to view the U.S. Prescribing Information | Canada Product Monograph.

QED has formed a strategic partnership with Helsinn to advance the oncology portfolio while maintaining sole ownership and development of infigratinib for non-oncology indication(s).

For more information, see our pipeline or email [email protected].

QED-Pipeline-Update-R7

Clinical Trials Currently Enrolling^*

The PROOF Trial is a Phase 3 trial evaluating oral infigratinib vs gemcitabine + cisplatin in first-line, FGFR2 fusion-positive CCA. Patients are randomized 2:1 to receive investigational, oral infigratinib 125 mg once daily for the first 3 weeks (21 days) OR gemcitabine with cisplatin on Days 1 and 8 of a 21-day cycle.

The PROOF 302 Trial is a Phase 3, multicenter, double-blind, randomized, placebo-controlled trial of infigratinib for the adjuvant treatment of subjects with invasive urothelial carcinoma with FGFR3 genomic alterations.

Subjects will be randomized in a 1:1 ratio to receive oral infigratinib or placebo, administered once daily for the first 3 weeks (21 days) of a 28-day treatment cycle for a maximum of 52 weeks.

An observational research study designed to learn more about the overall health, growth, and possible medical complications in children with achondroplasia (a bone growth disorder). No medication will be administered; however, children successfully enrolled in PROPEL for 6 months or more may be eligible for subsequent treatment trials sponsored by QED Therapeutics, including PROPEL 2.

References

Touat M et al. Clin Cancer Res. 2015;21(12):2684-2694.
Turner N et al. Nat Rev Cancer. 2010;10:116-129.
Katoh M. Nat Rev Clin Oncol. 2019;16:105-122.
Babina IS et al. Nat Rev Cancer. 2017;17:318-332.
TRUSELTIQ Prescribing Information. Brisbane, CA: QED Therapeutics, Inc.; [Month] 2021.
American Cancer Society. https://www.cancer.org/cancer/bile-duct-cancer/about/key-statistics. Accessed March 27, 2021.
Lamarca A et al. J Clin Med. 2020;9(9):2854.
Arai Y et al. Hepatology. 2014;59(4):1427-1434.
Kongpetch S et al. JCO Global Oncol. 2020;6:628-638.

Ross JS et al. Cancer. 2016;122(5):702-711.
Sfakianos JP et al. Eur Urol. 2015;68(6):970-977.
Moss TJ et al. Eur Urol. 2017;72(4):641-649.
Bagrodia A et al. J Urol. 2016;195(6):1684-1689.
Bagrodia A et al. Eur Urol Focus. 2019;5(3):365-368.
Audenet F et al. Clin Cancer Res. 2019;25(3):967-976.
Komla-Ebri D et al. J Clin Invest. 2016;126(5):1871-1884.
National Institutes of Health. https://ghr.nlm.nih.gov/condition/achondroplasia. Accessed April 1, 2021.
Legare JM et al. https://www.ncbi.nlm.nih.gov/books/NBK1152/. Accessed April 1, 2021.

1800 Owens St, 12th Floor, San Francisco, CA 94158

For additional information, reach out to [email protected]

Maps were disabled by the visitor on this site.